ARCH:TSXV ACHFF:OTC
  • Home
  • About usOur story, our approach
  • Our Science Pipeline, research & publications
    • Our Key Platforms
      • MetaBlok™Treating, organ injury caused by inflammation
      • AB569Treatment for Respiratory Pseudomonas aeruginosa Infections
      • BORGPeptide Solid Surface Interface
      • MetaMx™Brain Tumor Initiating Cell Targeting
    • Our PublicationsPeer-reviewed scientific publications
      • AB569
      • Brain Tumor Stem Cell Targeting
      • BORG Peptide Solid Surface Interface
      • Treatments for Inflammation
  • Our Team Management & lead scientists
    • Our ManagementGovernance, Executive, Board of Directors and Advisors
    • Our Principal ScientistsLearn about the scientists behind our technologies
      • MetaBlok™ and MetaMx™
      • AB569 & Respiratory Pseudomonas
      • BORG Peptide
      • Treatments for Inflammation
  • Investor Hub Investor relations, fundamentals
    • Fundamentals
      • Press Releases
      • Investor Information
      • Stock Performance
    • Reports and Filings
      • Management Discussion and Analysis
      • Annual and Quarterly Reports
      • Proxies and Information Circulars
      • Material Change Documents
      • Other SEDAR Filings
  • Contact Us

Arch Biopartners Forms Clinical and Medical Advisory Board for AB569

TORONTO, ONTARIO--(Marketwired - July 18, 2016) - Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced the formation of a clinical and medical advisory board for AB569, the Company's bactericidal drug for treating antibiotic resistant infections in lungs and the urinary tract.

In this capacity, the advisory board will provide guidance and expertise on obtaining regulatory approvals, human trial design and patient enrolment to enable first-in-human trials for AB569 in patients with chronic lung infections.

The new members of the clinical and medical advisory board are for the following diseases:

Cystic Fibrosis (CF):

Dr. Bruce Trapnell, MD, Director, Translational Pulmonary Science Center, Cincinnati Children's Hospital Medical Center (CCHMC), Professor of Medicine and Pediatrics, University of Cincinnati (UC) - Dr. Trapnell received his medical degree from the University of Maryland in 1985, medical internship and residency training at the Ohio State University Hospitals and completed a pulmonary medicine fellowship at the National Institutes of Health (NIH), where he then served as senior attending physician. Subsequently, he established the Division of Pulmonary and Virology Studies at Genetic Therapy, Inc., a subsidiary of Novartis AG, and served as Vice President before joining the faculty of CCHMC in 1997. Dr. Trapnell's work has focused on the molecular pathogenesis, diagnosis, and therapy of rare diseases including CF, the role of GM-CSF in alveolar macrophage function in health and disease, and human gene therapy.

Dr. Trapnell also serves as Director of the NIH-funded Rare Lung Diseases Clinical Research Consortium, Scientific Director of the Pulmonary Alveolar Proteinosis Foundation, Assistant Director of the Cincinnati Adult CF Care Center, and the Vice Chair of the Medical and Scientific Advisory Council of the Alpha-1 Foundation. He has served as a standing member of the NIH Lung Cellular and Immunobiology Study Section, received numerous awards including election to the Association of American Physicians and is a member of the National Health Council.

Dr. Patricia Joseph, MD, Professor of Medicine and Pediatrics, UC College of Medicine and Director of the Adult CF Center at the UC Medical Center - Dr. Joseph received her medical degree and then completed her combined residency in Medicine-Pediatrics from the University of Tennessee College of Medicine in 1988. She then went on to complete a Fellowship in Pulmonary and Critical Care at Massachusetts General Hospital. Dr. Joseph has dedicated her professional career to the care of patients with CF and has worked to improve patient health by focusing on patient centered outcomes. Throughout her career she has participated in numerous clinical trials, with a focus on adult CF lung disease.

Dr. Joseph is currently co-director (Adults), with Dr. J.P. Clancy (Pediatrics), of the CF Foundation Therapeutics Development Network (TDN). Through efficient study design, optimized clinical trial execution and high-quality data, the TDN's objective is to help speed the delivery of new and better therapies to people with CF.

Dr. John P. Clancy, MD, Professor, Cincinnati Children's Hospital Medical Center - Dr. Clancy has served in several leadership roles at University of Alabama, CCHMC and within the international CF community. Some of his leadership roles include membership on the CFF Clinical Research Committee (2003 to present), the CFF-TDN Steering Committee (2002 to 2007), the CFF-TDN Translational Research Center Committee (2008 to present), DSMB membership for the Rare Lung Disease Consortium within the NIH Rare Disease Research Network (2005 to 2009, Chairman from 2010 to present); organizing committee membership for the North American CF Conference (2003 to present) and the European CF Society (2010), co-chair of the CFFT Biomarkers Consortium (2010 to present), member of the Promotion and Tenure Committee for the UAB Department of Pediatrics (2003 to 2010) and the UAB SOM (2007 to 2010, including committee chair).

He has been the initial recipient of three endowed chairs, including the Raymond K. Lyrene Chair in Pediatric Pulmonary Medicine at the University of Alabama (2005), and the Tom Boat Chair in Cystic Fibrosis Clinical and Translational Research at Cincinnati Children's (2011) and the Gunnar Esiason/Cincinnati Bell Chair in Life Sciences Research (2013).

Chronic Obstructive Pulmonary Disease (COPD):

Dr. Ralph J. Panos, MD, Chief of Medicine, Cincinnati Veterans Affairs Medical Center (CVAMC)- Dr. Panos is the Chief of Medicine and Medical Director of the Veterans Integrated Service Network 10 TeleICU Program at the Cincinnati VAMC. Dr. Panos obtained undergraduate and medical degrees from Brown University; performed his internal medical residency and chief residency at the University of Maryland in Baltimore; and, completed a pulmonary fellowship at the University of Colorado. His academic appointments include Northwestern University, Penn State, and now the University of Cincinnati. His research currently has a clinical and translational focus centering on interstitial lung disease and COPD.

He has worked at the Cincinnati VAMC for over 10 years holding positions as the Chief of the Pulmonary, Critical Care, and Sleep Medicine Section and Associate Chief of Staff for Research and Development. He serves as President and Chairman of the Board of the Cincinnati Education &Research for Veterans Foundation (CERV). Dr. Panos is Professor of Medicine, Pulmonary, Critical Care, and Sleep Medicine, and Associate Chief of Medicine for Veterans Affairs, Department of Internal Medicine, University of Cincinnati College of Medicine.

About AB569 and Anti-biotic resistant airway infections in CF and COPD patients

AB569 was invented by Dr. Daniel Hassett, Professor at the UC College of Medicine, to treat antibiotic resistant bacterial lung infections, which is a significant problem for patients with either CF or COPD. AB569 has been exclusively licensed to Arch by UC.

AB569, as a bactericidal compound, constitutes an innovative potential treatment for dealing with pulmonary bacterial infections that are resistant to traditional antibiotics. In pre-clinical studies, AB569 has demonstrated significant ability to kill many types of Gram-negative and Gram-positive bacteria.

Cystic fibrosis patients are predisposed to bacterial lung infections due to abnormal mucus production in the lungs and airways. In particular, Pseudomonas aeruginosa infects 40% of CF patients between the ages of 6 and 10 years of age. By the age of 17, the frequency of infection increases to 60% and reaches approximately 75% of all CF patients between the ages of 25 and 34.

The mucoid form of P. aeruginosa is a very challenging infection to treat due to its high resistance to both antibiotics and phagocyte-mediated killing. Once patients present with the mucoid form of P. aeruginosa, their overall lung function precipitously declines, resulting in a poor overall prognosis.

COPD is a major health problem worldwide and its prevalence is increasing (315,000,000 patients world-wide), ranked by the World Health Organization as the third leading cause of death. COPD is a general term to describe progressive lung diseases which includes chronic bronchitis, emphysema, and non-reversible asthma.

Like CF patients, people with COPD have compromised immune systems and respiratory conditions that are vulnerable to chronic bacterial infections that often resist antibiotics.

The COPD Foundation estimates that there are over 24 million people in the US that have COPD with most cases caused by inhaling pollutants, usually from smoking or exposure to lung pollutants in the workplace.

There are approximately 36,000 CF patients in the USA and the mean prevalence of CF is approximately 0.74 cases per 10,000 people among 27 European Union countries.

Arch was recently granted orphan drug designation for AB569's active ingredients for the treatment of CF patients with chronic lung infections from both the US Food and Drug Administration and the European Medicines Agency.

About Arch Biopartners

Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.

Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; MetaMx, which targets elusive brain tumor initiating cells; Metablok, a potential treatment for sepsis and cancer metastasis; and, 'Borg' peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.

For more information on Arch Biopartners, other public documents Arch has filed on SEDAR and its technologies including, please visit www.archbiopartners.com.

The Company currently has 53,849,679 common shares outstanding.

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

PDF

Press Releases 2020
December 29th 2020

Arch Biopartners Closes Non-Brokered Private Placement

December 15th 2020

Arch Biopartners Receives Government of Canada Funding to Support Phase II Therapeutic Trial of Metablok for COVID-19

December 10th 2020

VA San Diego Healthcare System Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

November 5th 2020

Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

October 16th 2020

First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

October 7th 2020

Arch Biopartners Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide; Begins Screening Patients in Florida

September 10th 2020

Arch Biopartners Receives Ethics Committee Approval in Turkey for Phase II Trial for LSALT Peptide

September 1st 2020

Arch Biopartners Announces Application to the Turkish Ministry of Health to Conduct Phase II Trial for Treatment of Complications in COVID-19 patients

August 21st 2020

Arch Biopartners Obtains DTC Eligibility for its Common Shares on OTCQB

August 18th 2020

Arch Biopartners to Hold LSALT Peptide Webinar Today at 11am EST

August 7th 2020

Arch Biopartners to Hold LSALT Peptide Webinar and Q&A Session August 18, 2020 at 11am EST

August 4th 2020

Arch Biopartners Receives Independent Institutional Review Board Approval for Phase II Trial for LSALT Peptide

July 28th 2020

Broward Health Medical Center Becomes First Clinical Site in U.S. for Phase II Trial for LSALT Peptide

July 14th 2020

Arch Biopartners Engages Global CRO to Conduct LSALT peptide (Metablok) Phase II trial for Treatment of Complications in COVID-19 Patients in the U.S.

June 30th 2020

Arch Biopartners Closes Non-Brokered Private Placement

June 24th 2020

Arch Biopartners Arranges Non-Brokered Private Placement

June 16th 2020

FDA Grants Arch Biopartners Permission to Proceed with Phase II trial to Evaluate Metablok (LSALT peptide) for the Treatment of COVID-19 patients

June 15th 2020

Arch Biopartners Announces FDA Acknowledgement of its Investigational New Drug Application for Metablok (LSALT peptide)

June 11th 2020

Grant of Options

June 8th 2020

Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)

May 19th 2020

Arch Biopartners Expands the Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19

May 8th 2020

Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial

April 23rd 2020

Arch Biopartners Submits Application to Health Canada to Conduct COVID19 Phase II Human Trial for Metablok to Prevent Lung and Kidney Inflammation

March 31st 2020

Arch Biopartners Releases New Video Showing Metablok Reducing Lung Inflammation in an Animal Model

March 24th 2020

Arch Biopartners Discloses New Patent Filing For Novel Drug Candidates To Prevent Lung Inflammation

March 17th 2020

Arch Biopartners Safely Completes Expanded Dosing of METABLOK in Phase I Human Trial and Begins Focus on Phase II Trial

March 4th 2020

Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies

February 21st 2020

Arch Scientist Publishes Data on the Pre-Clinical Efficacy of AB569 in Killing of Drug Resistant Bacteria

February 6th 2020

Arch Biopartners Closes Convertible Note Financing

Press Releases 2019
December 18th 2019

Arch Biopartners Announces Metablok Achieves Primary Endpoints of Safety and Tolerability in Phase I Trial

December 4th 2019

Arch Biopartners Announces Issuance of U.S. Patent for Dipeptidase-1 Inhibitor Drug for Use in Acute Kidney Injury

November 7th 2019

Arch Provides Interim Update on Phase I Trial for Metablok (LSALT Peptide)

August 22nd 2019

Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate Metablok in the Prevention of Inflammation and Organ Damage

June 19th 2019

Arch Biopartners Announces Start of Phase I Human Trial for Metablok

March 19th 2019

UPDATE - Arch Biopartners Receives Approval to Perform Phase I Clinical Trial for Metablok in Australia

February 7th 2019

Arch Biopartners Awarded NRC-IRAP Funding to Further Develop Metablok Drug Program

January 29th 2019

Arch Biopartners Closes Convertible Note Financing

January 24th 2019

Arch Biopartners Arranges Convertible Note Financing

Press Releases 2018
December 11th 2018

Arch Biopartners Forms New Subsidiary to Pursue a Phase I Trial in Australia for Metablok (LSALT Peptide)

October 29th 2018

Arch Biopartners Provides Toxicology Update for Metablok

September 26th 2018

Arch Biopartners Announces Completion of GMP Manufacturing of Metablok Vials

August 14th 2018

Arch Biopartners Engages Dalton Pharma Services for GMP Manufacturing of Metablok

June 26th 2018

Arch Biopartners Receives $332,750 From the Exercise of Warrants

June 19th 2018

Arch Biopartners to Seek Regulatory Guidance From the U.S FDA for AB569

May 22nd 2018

Arch Biopartners Engages Nucro-Technics To Complete Toxicology Studies To Support Investigational New Drug Application For Metablok

May 16th 2018

Arch Biopartners Announces Listing on OTCQB Exchange

May 8th 2018

Arch Biopartners Completes Pre-IND Meeting with U.S. FDA on LSALT Peptide for Preventing Acute Kidney Injury in Cardiac Surgery Patients

March 27th 2018

Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569, Designed to Target Chronic Infection and Antibiotic Resistance

March 21st 2018

Arch Biopartners Granted Pre-Ind Meeting With FDA for Candidate Drug to Prevent Acute Kidney Injury

March 9th 2018

Arch Biopartners Closes $1.25M Non-Brokered Private Placement Financing

February 27th 2018

Arch Biopartners Announces Start of GMP Manufacturing for Metablok at CSBio

February 13th 2018

Arch Biopartners Announces AB569 Phase I Human Trial Begins Patient Recruitment and Enrollment Stage

Press Releases 2017
December 6th 2017

Arch Biopartners Announces Completion of GMP Manufacturing of AB569 and Start Date of Phase I Trial

November 1st 2017

Arch Biopartners Engages Nucro Technics to Begin Toxicology Studies for Metablok

October 10th 2017

Arch Biopartners Initiates Manufacturing Process for Metablok

September 28th 2017

Arch Biopartners' GMP Manufacturing of AB569 Progresses to Final Production Stage

September 12th 2017

Arch Biopartners Increases Non-Brokered Private Placement Financing

July 27th 2017

Arch Biopartners Provides Update on GMP Manufacturing of AB569

July 24th 2017

Arch Biopartners Retains Market Maker and Arranges Non Brokered Private Placement Financing

May 4th 2017

Arch Biopartners Announces Start of GMP Manufacturing for AB569 at Dalton Pharma Services

April 18th 2017

Grant of Options to Directors, Officers and Scientists

April 13th 2017

Arch Biopartners' Lead Anti-Bacterial Drug Candidate AB569 to Enter Investigator-Sponsored Phase I Human Trial

February 28th 2017

Arch Biopartners Closes Non-Brokered Private Placement Financing

February 23rd 2017

Arch Biopartners Announces TSXV Stock Ticker Symbol Change to "ARCH"

February 21st 2017

Arch Biopartners Announces Non-Brokered Private Placement Financing

Press Releases 2016
December 12th 2016

Arch Biopartners Appoints Patrick Vink to Board of Directors

October 27th 2016

Arch Biopartners Collaborates With Team at Cincinnati Veterans Affairs Medical Center to Prepare Phase I and II Human Trial Protocol and Application for AB569

October 11th 2016

Arch Biopartners Announces Issuance of U.S. Patent for Metablok

August 10th 2016

Arch Biopartners Engages Catalent to Begin Manufacturing Process for AB569

July 18th 2016

Arch Biopartners Forms Clinical and Medical Advisory Board for AB569

July 5th 2016

Arch "Borg" Peptide Coating Displays Anti Corrosion Performance on Stainless Steel

June 1st 2016

Arch Biopartners' AB569 Receives Final Approval from European Commission for Orphan Designation for Cystic Fibrosis

April 26th 2016

Arch Biopartners' AB569 Receives Positive Opinion from EMA COMP for Orphan Designation for Cystic Fibrosis

March 16th 2016

Arch Biopartners Enters Exclusive License Agreement With University of Cincinnati for AB569

March 1st 2016

Arch Scientists Publish Data on the Efficacy and Mechanism of Action of Lead Drug Candidate AB569

February 3rd 2016

Arch Biopartners Submits Orphan Drug Application for AB569 to European Medicines Agency

January 6th 2016

Arch Biopartners, McMaster Scientists, Expand MetaMx Collaboration with Mitacs Award

Press Releases 2015
December 1st 2015

Arch Biopartners Provides MetaMx Development Update

November 13th 2015

Arch Biopartners Receives Orphan Drug Designation from FDA for AB569

October 21st 2015

Arch Biopartners Retains Virtus Advisory to Provide Investor Relations Services

September 17th 2015

Arch Biopartners: AB569 Successfully Completes Pre-Clinical Validation Studies

August 5th 2015

Arch Biopartners Announces Issuance of U.S. Patent for Brain Tumor Targeting Peptides

August 4th 2015

Arch Biopartners Announces Issuance of a Second U.S. Patent for Peptide Solid Surface Interface

July 23rd 2015

Arch Scientists Use 'BORG' Peptides to Improve Biocompatibilty of Polysulfone for Use in Dialysis

June 8th 2015

Dr. Sheila Singh, MD PhD. Joins Arch Biopartners as Medical and Clincial Advisor

April 1st 2015

Arch Biopartners 2015 AGM Results and Technology Status Update

March 18th 2015

Arch Biopartners Identifies Candidate Drug to Treat Psuedomonas Respiratory Infections

February 25th 2015

Arch Biopartners Announces Issuance of U.S. Patent for Peptide Solid Surface Interface

February 19th 2015

Arch Biopartners Receives Final Approval to List on TSX Venture Exchange

January 26th 2015

Arch Biopartners Completes Private Placement

January 16th 2015

Arch Biopartners Receives Conditional Approval for Listing on TSXV

January 6th 2015

Arch Biopartners Announces Private Placement

Press Releases 2014
November 26th 2014

Arch Biopartners Completes Clinical Development Plan for MetaMx

October 15th 2014

Arch Biopartners Introduces Metablok, a Novel Therapeutic Candidate for Blocking Sepsis, Cancer Metastasis

August 21st 2014

Arch Biopartners Appoints Adrian Haigh to Board of Directors

May 29th 2014

Arch Biopartners Hires d3 Medicine to Develop a Human Trial for Brain Tumor Targeting Technology

April 17th 2014

Arch Biopartners Appoints Claude Allary to Board of Directors

March 28th 2014

Arch Biopartners Enters Option to License University of Cincinnati Patent for Treating Bacterial Respiratory Infections

March 12th 2014

Arch Biopartners Announcement

February 25th 2014

Arch Biopartners Completes Private Placement and Receives NRC Funding

Press Releases 2013
November 20th 2013

Brain Tumor Cell Targeting Technology: Data to Be Presented at the Society of Neuro-Oncology Quadrennial Meeting

September 17th 2013

Arch Biopartners Appoints Former Roche Executives Patrick Smith and Craig Rayner as Drug Development Advisors

September 12th 2013

Arch Biopartners Announces Issuance of U.S. Patent for Brain Tumor Cell Targeting Technology

August 14th 2013

Arch Biopartners Joins the Life Sciences Canadian Technology Accelerator in San Francisco

June 6th 2013

Arch Biopartners Announces Issuance of Additional U.S. Patent for Biofilm Inhibitor

April 22nd 2013

Brain Tumour Targeting Team Awarded Additional Funding

April 3rd 2013

Arch Scientists Publish Data Linking Inflammatory Enzymes to Inflammatory Bowel Disease

April 1st 2013

Arch Biopartners Announces Shareholder Approval to Allow Listing to Move to New Exchange

Press Releases 2012
December 7th 2012

Arch Scientists Publish New Stainless Steel Anti Corrosion and Biofilm Data

October 18th 2012

Dr. Julia Liu to Present at American College of Gastroenterology Annual Meeting Oct 22, 2012

September 6th 2012

Arch Biopartners Enters Option to Acquire Irritable Bowel Syndrome Diagnostic Technology

August 21st 2012

Arch Scientists Successfully Image Brain Tumour Initiating Cells Using MRI

March 15th 2012

Arch Awarded Funding from the Government of Canada to Develop Brain Tumour Targeting Technology

February 28th 2012

Arch Scientists to Lead Anti Corrosion Project for Auto Industry

January 24th 2012

Arch Biopartners Appoints Claude Allary as Special Advisor

Press Releases 2011
December 19th 2011

Arch Scientists Inhibit Biofilm Formation and Increase Hardness on Titantium

November 7th 2011

Arch Biopartners Engages Intertek Cantox to Devise Drug Development Plan for Lead Cancer Compound

September 7th 2011

Arch Biopartners Identify Lead Compound for Pancreatic Cancer and Non Small Cell Lung Cancer

July 18th 2011

Arch Biopartners Hires Investor Relations Firm

July 14th 2011

Arch Biopartners Announces Issuance of New U.S. Patent for Biofilm Inhibitor

July 6th 2011

Arch Biopartners, U of Calgary Extend Agreement

June 27th 2011

Arch Biopartners Enters Agreement to Develop Prototype Diagnostic Imaging Agents for Brain Tumor Stem Cells

June 23rd 2011

Arch Biopartners Scientists Awarded Funding to Further Develop Brain Tumour Targeting Technology

May 24th 2011

Arch Scientists to Present at ESF-LFUI Conference in Austria

May 10th 2011

Arch Scientists Create New Bio-Organic Metal That Is Harder, Resists Corrosion

April 11th 2011

Arch Cancer Therapeutics' Technology Update

Email News Subscriptions

Arch Biopartners send our press releases automatically via email. Check the boxes below to also receive updates on our science and investor news.
You'll receive an email confirming your subscription. Click the link in the email and you'll be set to go. You can unsubscribe at any time, and we will never share your email address.
Arch Biopartners
  • Home
  • About us
  • Our Science
    • Our Key Platforms
    • Our Publications
  • Our Team
    • Our Management
    • Our Principal Scientists
  • Investor Hub
    • Fundamentals
    • Reports and Filings
  • Contact Us
Contact us
+1 647 428 7031
info@archbiopartners.com
Mailing Address
27 St. Clair Ave East
P.O. Box 305
Toronto, Ontario
Canada M4T 2M5
Copyright Arch BioPartners 2020. All Rights Reserved. Legal notices.
PAGE TOP | TYPE SIZE | | RESET
Press Releases
  • Home
  • About us
  • Our Science
    • Our Key Platforms
      • MetaBlok™
      • AB569
      • BORG
      • MetaMx™
    • Our Publications
      • AB569
      • Brain Tumor Stem Cell Targeting
      • BORG Peptide Solid Surface Interface
      • Treatments for Inflammation
  • Our Team
    • Our Management
    • Our Principal Scientists
      • MetaBlok™ and MetaMx™
      • AB569 & Respiratory Pseudomonas
      • BORG Peptide
      • Treatments for Inflammation
  • Investor Hub
    • Fundamentals
      • Press Releases
      • Investor Information
      • Stock Performance
    • Reports and Filings
      • Management Discussion and Analysis
      • Annual and Quarterly Reports
      • Proxies and Information Circulars
      • Material Change Documents
      • Other SEDAR Filings
  • Contact Us